Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer
Fuente:
Wiley Open Access
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Veröffentlicht: |
Wiley
2024
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1867013077867692032 |
|---|---|
| author | Agnieszka Krzyzanowska Debra F. Higgins Stephen Barron Tony Loughman Amanda O'Neill Katherine M. Sheehan Chan‐Ju Angel Wang Bozena Fender Leah McGuire Joanna Fay Anthony O'Grady Des O'Leary R. William Watson Anders Bjartell William M. Gallagher |
| author_facet | Agnieszka Krzyzanowska Debra F. Higgins Stephen Barron Tony Loughman Amanda O'Neill Katherine M. Sheehan Chan‐Ju Angel Wang Bozena Fender Leah McGuire Joanna Fay Anthony O'Grady Des O'Leary R. William Watson Anders Bjartell William M. Gallagher Agnieszka Krzyzanowska Debra F. Higgins Stephen Barron Tony Loughman Amanda O'Neill Katherine M. Sheehan Chan‐Ju Angel Wang Bozena Fender Leah McGuire Joanna Fay Anthony O'Grady Des O'Leary R. William Watson Anders Bjartell William M. Gallagher |
| collection | Wiley Open Access |
| contents | Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer Agnieszka Krzyzanowska Debra F. Higgins Stephen Barron Tony Loughman Amanda O'Neill Katherine M. Sheehan Chan‐Ju Angel Wang Bozena Fender Leah McGuire Joanna Fay Anthony O'Grady Des O'Leary R. William Watson Anders Bjartell William M. Gallagher BJUI Compass AbstractObjectivesThis study aimed to clinically validate the six‐gene prognostic molecular clinical risk score (MCRS) for the prediction of aggressive prostate cancer in diagnostic biopsy tissue.MethodsMCRS was evaluated in prostate biopsy tissue from a Swedish cohort of men with prostate cancer (UPCA, n = 100). The primary outcome of adverse pathology and secondary outcomes of high primary Gleason (≥G4) and high pathological T‐stage (≥T3) were assessed by likelihood ratio statistics and area under the receiver operating characteristic curves from logistic regression models; time to biochemical recurrence was assessed by likelihood ratio statistics and C‐indexes from Cox proportional hazard regression models.ResultsBiopsy MCRS was significantly prognostic (p < 0.0001) and added significant prognostic value to clinico‐pathological features for adverse pathology, high primary Gleason and high pathological T‐stage (p < 0.0001). MCRS was prognostic for biochemical recurrence and added some, albeit non‐significant, prognostic value to clinical risk stratifiers, which could reflect the low number of recurrence events in the cohort.ConclusionBiopsy‐based MCRS improves risk stratification over standard clinical and pathological information and optimises patient management after diagnosis of prostate cancer. 10.1002/bco2.474 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/bco2.474 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_bco2_474 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer Agnieszka Krzyzanowska Debra F. Higgins Stephen Barron Tony Loughman Amanda O'Neill Katherine M. Sheehan Chan‐Ju Angel Wang Bozena Fender Leah McGuire Joanna Fay Anthony O'Grady Des O'Leary R. William Watson Anders Bjartell William M. Gallagher BJUI Compass Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer Agnieszka Krzyzanowska Debra F. Higgins Stephen Barron Tony Loughman Amanda O'Neill Katherine M. Sheehan Chan‐Ju Angel Wang Bozena Fender Leah McGuire Joanna Fay Anthony O'Grady Des O'Leary R. William Watson Anders Bjartell William M. Gallagher BJUI Compass AbstractObjectivesThis study aimed to clinically validate the six‐gene prognostic molecular clinical risk score (MCRS) for the prediction of aggressive prostate cancer in diagnostic biopsy tissue.MethodsMCRS was evaluated in prostate biopsy tissue from a Swedish cohort of men with prostate cancer (UPCA, n = 100). The primary outcome of adverse pathology and secondary outcomes of high primary Gleason (≥G4) and high pathological T‐stage (≥T3) were assessed by likelihood ratio statistics and area under the receiver operating characteristic curves from logistic regression models; time to biochemical recurrence was assessed by likelihood ratio statistics and C‐indexes from Cox proportional hazard regression models.ResultsBiopsy MCRS was significantly prognostic (p < 0.0001) and added significant prognostic value to clinico‐pathological features for adverse pathology, high primary Gleason and high pathological T‐stage (p < 0.0001). MCRS was prognostic for biochemical recurrence and added some, albeit non‐significant, prognostic value to clinical risk stratifiers, which could reflect the low number of recurrence events in the cohort.ConclusionBiopsy‐based MCRS improves risk stratification over standard clinical and pathological information and optimises patient management after diagnosis of prostate cancer. 10.1002/bco2.474 http://creativecommons.org/licenses/by/4.0/ |
| title | Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer |
| topic | BJUI Compass |
| url | https://bjui-journals.onlinelibrary.wiley.com/doi/10.1002/bco2.474 |